Stockreport

Inhibrx shares surge after bone cancer drug slows disease progression in trial [Yahoo! Finance Canada]

Inhibrx, Inc.  (INBX) 
PDF In the 206-patient study, the drug, ozekibart, extended the time patients lived without their cancer worsening to 5.52 months, compared with 2.66 months for those on pl [Read more]